Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors.

Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors.

Eur J Med Chem. 2019 Feb 12;167:485-498

Authors: Yao H, Xu F, Wang G, Xie S, Li W, Yao H, Ma C, Zhu Z, Xu J, Xu S

Abstract
A series of novel B and C-rings truncated deguelin derivatives have been designed and synthesized in the present study as heat shock protein 90 (Hsp90) inhibitors. The synthesized compounds exhibited micromolar antiproliferative potency toward a panel of human cancer cell lines. Their structure-activity relationships (SARs) were investigated in a systematic manner. Compound 21c was identified to have high Hsp90 binding potency (60 nM) and caused degradation of client proteins through ubiquitin proteasome system. Further biological studies showed that compound 21c induced a dose-dependent S and G2-phase cell cycle arrest on human breast cancer MCF-7 cells. Flow cytometry and Western blot analyses confirmed that compound 21c caused apoptosis of MCF-7 cells. In addition, compound 21c showed much potent inhibition on the migration and invasion of MCF-7 cells. Taken together, these results suggest that 21c might be a promising lead compound for further development of Hsp90 inhibitors.

PMID: 30784881 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader https://ift.tt/2GVvaph